©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5172-5179
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5172
Table 1 Comparison of clinical data between the two groups, n %
| Clinical information | S-1 group (n = 47) | Gemcitabine group (n = 47) | χ2/t | P value |
| Gender | 0.092 | 0.761 | ||
| Male | 27 (57.45) | 26 (55.32) | ||
| Female | 20 (42.55) | 21 (44.68) | ||
| Types | 0.361 | 0.548 | ||
| Squamous carcinoma | 23 (48.94) | 25 (53.19) | ||
| Adenocarcinoma | 24 (51.06) | 22 (46.81) | ||
| TNM staging | 0.130 | 0.719 | ||
| Phase IIIB | 36 (76.60) | 37 (78.72) | ||
| Phase IV | 11 (23.40) | 10 (21.28) | ||
| Age (yr) | 56.95 (4.15) | 56.17 (4.01) | 0.927 | 0.357 |
| Weight (kg) | 53.94 (3.52) | 54.09 (3.61) | 0.204 | 0.839 |
| BMI (kg/m2) | 21.14 (3.21) | 21.51 (3.45) | 0.538 | 0.592 |
- Citation: Cheng XW, Leng WH, Mu CL. Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients. World J Clin Cases 2020; 8(21): 5172-5179
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5172.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5172